ライフサイエンスコーパス: co-transporter

1 bumetanide, an inhibitor of the Na+-K+-2Cl- co-transporter.

2 ng II) was shown to regulate the MD Na:2Cl:K co-transporter.

3 at least in part, through an apical Na:2Cl:K co-transporter.

4 in C. elegans and the recently cloned human co-transporter.

5 TP and substrates by acting as a proton/drug co-transporter.

6 secondary to restoration of affinity of the co-transporter.

7 predominantly through the NaPi-2b (SLC34a2) co-transporter.

8 otif result in defects in the ER exit of the co-transporter.

9 ed for ER exit and surface expression of the co-transporter.

10 lial Na(+) channel (ENaC) and Na(+) -coupled co-transporters.

11 and NKCC2, and also affect other related ion co-transporters.

12 oding electroneutral cation-coupled chloride co-transporters.

13 ocess of a functional human sodium/D-glucose co-transporter 1 (hSGLT1) in Pichia pastoris as represen

14 rbonic anhydrase 4 (CA4) and Na+/bicarbonate co-transporter 1 (NBC1) is specifically expressed in the

15 ones, alpha-defensin, mucin 2, Na(+)/glucose co-transporter 1 (SGLT1) and transcription factors, Hes1

16 he upregulation of the active sodium/glucose co-transporter 1 (SGLT1) was found to confer the develop

17 of Cl(-) loaders such as the Na(+)K(+)2Cl(-) co-transporter 1 (Slc12a2) over Cl(-)extruders of uniden

18 eptide transporter 1 (PepT1), sodium/glucose co-transporter-1 (SGLT-1), potassium inwardly-rectifying

19 argininosuccinate synthase 1, sodium/glucose co-transporter-1, and cystic fibrosis transmembrane cond

20 tablish that the "neuron-specific" K(+)Cl(-) co-transporter 2 (KCC2, Slc12a5) is expressed in several

21 nnel (gammaENaC), sodium-potassium -chloride co-transporter 2 (NKCC2), sodium chloride co-transporter

22 ression was elevated, whereas sodium-glucose co-transporter 2 (Sglt2) expression was down-regulated i

23 y predict the response to the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin, which

24 kidney protective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors are not fully elucid

25 indication for the use of the sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagliflozin and em

26 Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a beneficial im

27 Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated po

28 Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascul

29 Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria a

30 1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the cl

31 nsin II receptor blockers and sodium-glucose co-transporter 2 (SGLT2) inhibitors.

32 Therapeutic inhibition of the sodium-glucose co-transporter 2 (SGLT2) leads to substantial loss of en

33 i et al. found that targeting sodium-glucose co-transporter 2 (SGLT2) promoted immune clearance of se

34 n about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population

35 We aimed to assess effects of sodium glucose co-transporter 2 inhibition on bioimpedance-derived "Flu

36 data that intervention using sodium-glucose co-transporter 2 inhibition or gastric bypass surgery ca

37 Sodium-glucose co-transporter 2 inhibition reduces the risk of hospital

38 Lowering blood sugar by the sodium-glucose co-transporter 2 inhibitor empagliflozin provides cardia

39 eserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly r

40 th dapagliflozin, a selective sodium-glucose co-transporter 2 inhibitor.

41 Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a p

42 iuretic effects achieved with sodium glucose co-transporter 2 inhibitors (SGLT2i) may offset fluid re

43 as to determine the effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on incident diabete

44 Sodium glucose co-transporter 2 inhibitors (SGLT2i) reduce the risk of

45 To investigate how sodium-glucose co-transporter 2 inhibitors (SGLT2is) add-on therapy for

46 ceptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favorably influence the clin

47 clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients

48 cial cardiovascular effect of sodium glucose co-transporter 2 inhibitors in T2DM.

49 Sodium glucose co-transporter 2 inhibitors may reduce cardiovascular an

50 rmone receptor beta agonists, sodium-glucose co-transporter 2 inhibitors, and agents to modify de nov

51 nstrated the effectiveness of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 rec

52 otensin receptor blockers, or sodium glucose co-transporter 2 inhibitors, often produce acute treatme

53 8% were receiving concomitant sodium-glucose co-transporter 2 inhibitors.

54 ptide 1 receptor agonists and sodium-glucose co-transporter 2 inhibitors.

55 We inhibited the sodium-glucose co-transporter 2 using dapagliflozin (SGLT2i) to test a

56 nal proximal tubules, such as sodium-glucose co-transporter 2, are attractive therapeutic targets for

57 an absence of the sodium-potassium-chloride co-transporter 2, NKCC2.

58 imal tubule Na(+)/H(+) exchanger 3, Na(+)/Pi co-transporter 2, phosphorylated Na(+)/K(+)/Cl(-) cotran

59 at present, metformin and the sodium-glucose-co-transporter 2-inhibitor empagliflozin seem to be espe

60 Sodium-glucose co-transporters 2 (SGLT-2) inhibitors have emerged as a

61 gliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition reduced the combined

62 short-term treatment with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced

63 diovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and ca

64 precise in some cases (e.g., sodium-glucose co-transporter-2 (SGLT2) inhibitors for type 2 diabetes-

65 Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several benefic

66 Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficia

67 The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney failure, p

68 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce glycaemia and

69 ting key transporters such as sodium-glucose co-transporter-2 (SGLT2), sodium-potassium-chloride cotr

70 he first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFp

71 rapy or on dual metformin and sodium-glucose co-transporter-2 inhibitor (SGLT2-I) therapy.

72 inuria-lowering effect of the sodium-glucose co-transporter-2 inhibitor dapagliflozin with and withou

73 physiological effects of the sodium-glucose co-transporter-2 inhibitor empagliflozin on intact exper

74 f metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor, a baseline glycated haemoglo

75 tolerated) with or without a sodium-glucose co-transporter-2 inhibitor.

76 s study aimed to determine if sodium-glucose co-transporter-2 inhibitors (SGLT2i) use in diabetic pat

77 se-lowering drug classes, the sodium-glucose co-transporter-2 inhibitors and agents that target the i

78 Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ket

79 ptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for t

80 ifting CKD treatments such as sodium glucose co-transporter-2 inhibitors dramatically improve outcome

81 Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established

82 Treatment with sodium-glucose co-transporter-2 inhibitors induces an initial 3-5 ml/mi

83 rbidity benefit) so far being sodium-glucose co-transporter-2 inhibitors, finerenone and tirzepatide.

84 peptide-1 receptor agonists, sodium-glucose co-transporter-2 inhibitors, sulfonylureas, and thiazoli

85 s for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors.

86 Sodium-phosphate co-transporter 2a (NaPi2a) is predominantly expressed in

87 lateral membranes and prolonged the cycle of co-transporter activation, internalization and re-expres

88 ependent MD-NO production, the regulation of co-transporter activity by NO, and the possible interact

89 prevent the OSR1-induced enhancement of ion co-transporter activity in cells, further supporting the

90 utative SPAK2 form), which modestly inhibits co-transporter activity in vitro, is more abundant in th

91 Whilst much is known about the co-transporter activity of NKCC1 and its regulation by p

92 induces secondary axes, independently of its co-transporter activity.

93 t and that NO and Ang II independently alter co-transporter activity.

94 sting that Na(+)/K(+)/2Cl(-) (NKCC1/SLC12A2) co-transporter and ENaC are targets of Nedd4L in the col

95 Bumetanide, an inhibitor of the Na+-K+-2Cl- co-transporter and one of the mechanisms of regulatory v

96 n exporters, particularly sodium bicarbonate co-transporters and carbonic anhydrases, which were also

97 the wild type AtAMT1;2 functions as H(+)/NH3 co-transporter, as well as how the strict substrate coup

98 ds, phosphorylates, and stimulates the NKCC1 co-transporter at the CPE apical membrane.

99 ctivity and phosphorylation of NCC and NKCC2 co-transporters at the residues phosphorylated by SPAK.

100 hway regulator of the Na-dependent glutamine co-transporters, B0AT1 in villus cells and SN2 in crypts

101 or increased rates of degradation of mutant co-transporters, but was instead caused by defects in ma

102 The cation-chloride co-transporters (CCCs) have been identified as important

103 e TLR4-NF-kappaB signaling or the SPAK-NKCC1 co-transporter complex.

104 to form rapidly CFTR- and Na(+),K(+),2Cl(-) co-transporter-dependent cysts that were three- to six-f

105 We propose that SLC4A11 is an NH3/2H(+) co-transporter exhibiting unique characteristics.

106 pite an increase in AQP1, AQP3, and Na-K-2Cl co-transporter expression.

107 ter is distinct from the sodium-myo-inositol co-transporter found in many tissues and accounts for al

108 All tested variants were shown to reduce co-transporter function in Xenopus laevis oocytes.

109 ported the successful cloning of the choline co-transporter in Caenorhabditis elegans (CHO-1) and rat

110 nce of the secretory isoform of the Na-K-2Cl co-transporter in gerbil, rat and rabbit inner ear.

111 s in the spinal cord and the level of an ion co-transporter in motor neuron membranes required for no

112 We report herein the cloning of the choline co-transporter in the horseshoe crab, Limulus polyphemus

113 known about the activities of NKCC1 that are co-transporter independent.

114 Additional sodium-glucose co-transporter inhibitors are progressing in development

115 We conclude that several cation chloride co-transporters interact with SPAK and/or OSR1, and we h

116 s constrained by a Ca(2+)-dependent cycle of co-transporter internalization, degradation and re-expre

117 KCC1 is a broadly expressed Na(+)-K(+)-Cl(-) co-transporter involved in regulation of ion flux across

118 long-time considered "neuron-specific" KCC2 co-transporter is expressed in pancreatic islet beta-cel

119 cholinium-3 sensitive, high affinity choline co-transporter is rate limiting in the biosynthesis of a

120 her demonstrated that the expression of K-Cl co-transporter isoform 2 (KCC2) was not changed in anima

121 linked to the normal functioning of K + -Cl- co-transporter isoform 2 (KCC2) which maintains a low in

122 The K(+)-Cl(-) co-transporter KCC2 (SLC12A5) tunes the efficacy of GABA

123 that enhancing the activity of the chloride co-transporter KCC2 after SCI decreases electrophysiolog

124 xpression of the neuronal potassium-chloride co-transporter KCC2 in principal cortical neurons.

125 cellular potassium accumulation via the K/Cl co-transporter KCC2 in promoting GABA(A)-mediated excita

126 the expression and function of the K(+)Cl(-) co-transporter KCC2 within VTA GABAergic neurons.

127 in expression of GABA(A)R or of the chloride co-transporter KCC2, but rather with inhibition of KCC2

128 The potassium-chloride co-transporter KCC2, encoded by SLC12A5, plays a fundame

129 ed by hypofunction of the potassium-chloride co-transporter KCC2.

130 ich is set by the neuron-specific K(+)-Cl(-) co-transporter KCC2.

131 y plot analysis predicts the Limulus choline co-transporter (LChCoT) to have thirteen transmembrane d

132 ulate the activity of the sodium-bicarbonate co-transporter, leading to a hyperpolarization of the ne

133 nner ear and show that absence of functional co-transporter leads to structural damages in the inner

134 The affected gene encodes a sodium/solute co-transporter-like protein, designated SLC5A11 (or cupc

135 previously described SLC5A11-a sodium/solute co-transporter-like-(or cupcake) in Drosophila melanogas

136 This co-transporter may be a site for regulation of tubuloglo

137 y inhibition of monocarboxylate lactate-H(+) co-transporters (MCTs) with AR-C155858.

138 NK4 in inhibition of both thiazide-sensitive co-transporter-mediated Na+ reabsorption and K+ secretio

139 oteinuria are in LRP2 and CUBN, encoding the co-transporters megalin and cubilin, respectively, that

140 ls and some exchangers (i.e. Na(+)/H(+)) and co-transporters (Na(+)-HCO(3)(minus sign), Na(+)-K(+)-2C

141 The Na(+)/dicarboxylate co-transporter, NaDC-1, couples the transport of sodium

142 The Na+/dicarboxylate co-transporter, NaDC-1, from the kidney and small intest

143 protein levels of the renal sodium-phosphate co-transporter NaPi-IIa in the proximal convoluted tubul

144 l protein expression of the sodium-phosphate co-transporter NaPi-IIa, lower renal Klotho protein expr

145 etrieval of renal sodium dependent phosphate co-transporters (NaPi-IIa/c) from the brush border membr

146 ntified and characterized the sodium/sulfate co-transporter (NaS-1; Slc13a1) as an Fxralpha target ge

147 ion of the renal basolateral Na(+)-HCO(3)(-) co-transporter (NBC).

148 tions in the electrogenic sodium bicarbonate co-transporter NBCe1 and mice lacking NBCe1 have enamel

149 The electrogenic sodium bicarbonate co-transporter NBCe1 has been localized in mouse amelobl

150 s CA IX co-localizes with sodium bicarbonate co-transporter (NBCe1) and anion exchanger 2 (AE2) that

151 SLC4A7 encodes the electroneutral Na+/HCO3- co-transporter NBCn1 which regulates intracellular pH (p

152 loride/bicarbonate AEs and Na(+)-bicarbonate co-transporters (NBCs).

153 mice, leading to up-regulation of the Na-Cl co-transporter NCC, p-NCC and the development of salt-se

154 ts with islets of wild-type, Sodium/chloride co-transporter (NCC) (SLC12A3), and sodium-driven chlori

155 ith elevated activity of the sodium chloride co-transporter (NCC) and, accordingly, NCC abundance is

156 the dimeric IL18 receptor (IL18r) and Na-Cl co-transporter (NCC) on adipocytes.

157 ed natriuresis, and enhanced sodium chloride co-transporter (NCC) phosphorylation.

158 de co-transporter 2 (NKCC2), sodium chloride co-transporter (NCC), aquaporin 2 (AQP2), and EGFR abund

159 the related kinase WNK4 regulates the Na-Cl co-transporter (NCC), paracellular Cl- flux, and the K+

160 this segment through the actions of the NaCl co-transporter (NCC), which is regulated by the with-no-

161 ors: the IL18 receptor (IL18r) and the Na-Cl co-transporter (NCC).

162 we found that IL18 interacts with the Na-Cl co-transporter (NCC; also known as SLC12A3), a 12-transm

163 g serine-811 in the thiazide-sensitive Na-Cl co-transporter, NCC.

164 ation in the membrane expression of the NaCl co-transporter (NCCT) and the renal outer-medullary K ch

165 se (ERK)1 and -2-dependent Na(+)-K(+)-2Cl(-) co-transporter (NKCC) activity may contribute to total p

166 cellular proliferation, loss of the Na-K-Cl co-transporter NKCC1, and expression of androgen recepto

167 strate that inhibiting the juvenile chloride co-transporter NKCC1, which contributes to altered chlor

168 pendent on the basolateral Na(+)-K(+)-2Cl(-) co-transporter (NKCC1).

169 cretion by blockade of the Na(+)/K(+)/2Cl(-) co-transporter, NKCC1, of stimulated CFTR(+) jejunum pre

170 timulate the sodium, potassium, two chloride co-transporters, NKCC1 and NKCC2, and also affect other

171 absorb NaCl via the apical Na(+)/K(+)/2Cl(-) co-transporter NKCC2.

172 absorb NaCl via the apical Na(+)/K(+)/2Cl(-) co-transporter NKCC2.

173 sin level, aquaporin 2, or Na(+)-K(+)-2Cl(-) co-transporter NKCC2/BSC1 protein abundances or UT-A1 mR

174 Mutations in the renal specific Na-K-2Cl co-transporter (NKCC2) lead to type I Bartter syndrome,

175 to modulate aquaporin 2 (AQP2) and Na-K-2Cl co-transporter (NKCC2), pivotal factors in urinary conce

176 Na,K,2Cl co-transporter (NKCC2), the primary NaCl uptake pathway

177 full-length splice isoforms of the Na-K-2Cl co-transporter (NKCC2/BSC1) are expressed along the thic

178 vate the potassium-dependent sodium-chloride co-transporter, NKCC2, and thiazide-sensitive sodium-chl

179 Mutations in the apical Na-K-2Cl co-transporter, NKCC2, cause type I Bartter syndrome, a

180 MK, and earlier to mutations in the Na-K-2Cl co-transporter, NKCC2.

181 in TgHMW mice, whereas the renal Na(+)/P(i) co-transporter Npt2a mRNA was decreased.

182 The sodium phosphate co-transporters Npt2a and Npt2c play important roles in

183 rane expression of the sodium-dependent P(i) co-transporters, NPT2a and NPT2c, and thus suppresses th

184 bition of B0AT1 in villus cells by restoring co-transporter numbers in the BBM, whereas the stimulati

185 rane solute transfer in the sodium-dependent co-transporter OCTN2.

186 :2Cl-, Na+:K+:2HCO3-, K+:HCO3-, or Na+:HCO3- co-transporters, or any combination of these.

187 ing), cell-specific expression of Na+/2HCO3- co-transporters, or voltage-dependent Na+ channels.

188 and both were reduced by sodium bicarbonate co-transporter (P </= 0.0001) and carbonic anhydrase inh

189 ult of lower plasma [K(+) ], sodium chloride co-transporter phosphorylation was enhanced in the KO ki

190 be mediated by a sodium-dependent phosphate co-transporter, Pit-1 (Glvr-1).

191 s the recently described sodium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A

192 emonstrated that the marked reduction in the co-transporter protein levels was essentially due to inc

193 , the basolateral membrane Na(+)/K(+)/2Cl(-) co-transporter protein NKCC1(+), and NKCC1(-) mice were

194 iting glucose reabsorption by sodium glucose co-transporter proteins (SGLTs) in the kidneys is a rela

195 ce of aquaporin 1 (AQP1), AQP3, and Na-K-2Cl co-transporter proteins and a marked reduction of the ur

196 e high affinity and low affinity Na+/lactate co-transporters, respectively, in the kidney.

197 hlorizin, an inhibitor of the sodium-glucose co-transporter (SGLT), a component of a hypothesized alt

198 vestigate the dynamics of the sodium glucose co-transporter (SGLT1) upon substrate and inhibitor bind

199 s in the gene encoding for the Na(+)-glucose co-transporter SGLT2 (SLC5A2) associate with familial re

200 Sodium-glucose co-transporters (SGLTs) in the kidneys play a pivotal ro

201 cose transporters (GLUTs) and sodium-glucose co-transporters (SGLTs) may also function as glucose sen

202 (GLUTs) but not for sodium-dependent glucose co-transporters (SGLTs), which have recently been shown

203 These co-transporters share 57% homology at the amino acid lev

204 in the gene encoding the basolateral Na-K-Cl co-transporter Slc12a2 (Nkcc1, mBSC2) cause the deafness

205 via the kinases OXSR1 and STK39 and the ion co-transporter SLC12A2.

206 he kidney-specific type IIa sodium phosphate co-transporter (SLC34A1), the calcium-sensing receptor (

207 increased NKCC2 expression by increasing the co-transporter stability.

208 was increased from 25 to 150 mM, indicating co-transporter stimulation.

209 OXSR1 and STK39 kinases, and the SLC12A2 ion co-transporter that are required for post-transcriptiona

210 KCC2 is a neuron specific K(+)-Cl(-) co-transporter that controls neuronal chloride homeostas

211 KCC2 is a neuron-specific K(+)-Cl(-) co-transporter that maintains a low intracellular Cl(-)

212 pulmonary epithelial Npt2b sodium-phosphate co-transporter that results in accumulation of phosphate

213 he SLC12A family, a group of cation-chloride co-transporters that are targets of therapeutic drugs an

214 cturally similar to mammalian sodium/glucose co-transporters that transport sugar across the intestin

215 y abundances of the thiazide-sensitive Na-Cl co-transporter, the alpha-subunit of the epithelial sodi

216 is mediated by two isoforms of the Na-K-2Cl co-transporter: the absorptive isoform BSC1 (also called

217 We localized the co-transporter to key secreting epithelia of the mouse i

218 The Na(+)-K(+)-2Cl(-) co-transporter type 1 (NKCC1) is localized primarily thr

219 g mechanism, the sodium-potassium-2 chloride co-transporter, was significantly decreased, as was the

220 l exit of HCO3- via the electrogenic Na/HCO3 co-transporter, which is the subject of at least 10 muta

221 ulating the Na-Cl (NCC) and Na-K-2Cl (NKCC2) co-transporters, which regulate salt reabsorption in the

222 inhibiting the basolateral Na(+),K(+),2Cl(-) co-transporter with bumetanide, which effectively blocke

223 situations where P(Cl)/P(K) is low, the same co-transporters would instead permit RVIs but at the exp